UK: 7%, 4%/6%, 16%/79%/2%/4%. Within each country, burden of type 2 diabetes tended to increase with age among diabetic individuals (all-age, 18-24, 25-34, 35-44, 45-54, 55-64, 65-69 yrs: % pts):
PDB9 ESTIMATED INCIDENCE OF TESTOSTERONE DEFICIENCY IN AGING BRAZILIAN MEN AND THE CONSEQUENT COSTS OF NEW CASES OF OSTEOPOROSIS-RELATED HIP FRACTURES
Bahia L 1 , Teich V 2 1 Brazilian Society of Diabetes, Rio de Janeiro, Brazil, 2 MedInsight, Rio de Janeiro, Brazil OBJECTIVES: This study aimed to model the increase in osteoporosis-related fractures and the associated costs related with aging and testosterone deficiency (TD) in the male population above 65 years in the Brazilian Private Health System (PHS). METHODS: Population-based prospective cohorts established age-specific annual incidence rates of testosterone deficiency and the prevalence of osteoporosis in men. Based on these estimates, projections for the number of cases of men with testosterone deficiency, osteoporosis and fractures in the Brazilian male population above 65 years were computed. The national costs associated with hip fractures have been previously recorded as R$ 24,051 (US$14,402) per event. RESULTS: Among 1,164,379 male individuals above 65 years under the Brazilian PHS, 27,130 new cases of TD would be expected in one year. Considering an osteoporosis incidence of 6% and 12.3% for men with normal and deficient testosterone, respectively, 1709 new cases of osteoporosis attributed to TD would be expected. This would result in an annual absolute increase of 0.16% in non-vertebral fracture incidence in men between 65-69 years; 0.24% between 70-74 years; 0.32% between 75-79 years and 0.40% above 80 years. Each of these absolute increases represents a 105% relative increase in the incidence of non-vertebral fractures between men with TD relative to men without TD. Seventy-one new non-vertebral fractures and 13 new cases of hip fractures would be expected, resulting in incremental costs of R$318,002 (US$190, 420) for the Brazilian PHS. CONCLUSIONS: Male aging is associated with gradual decrease in circulating testosterone, which may be detrimental to bone. This model suggests that, for the Brazilian male population above 65 years, testosterone deficiency is associated with a significant increase in new cases of osteoporosis-related fractures in one year. Diagnosis and proper treatment of this condition could have a favorable impact in the prevention of this costly complication. For the present analysis patients with missing values for LDL-c, HDL-c or triglycerides (TGs) were excluded. Individual patient lipid profiles were compared with the recommended lipid targets for diabetic patients by the latest ADA consensus. RESULTS: A total of 493 patients were recruited, and 338 included in this analysis. Average age was 63.1 (SD 10.6) years, 46.7% were female, and mean time from diabetes diagnosis was 8.6 (SD 5.3). The lipid parameter most frequently not at target was LDL-c (79.6%), followed by TGs (42.9%) and HDL-c (37.6%). 17.5% of patients had the three lipid parameters out of goal, and 31.4% had two of them not at target. Out of the 338 patients only 20 (a 6% approx.) presented all three lipid parameters at the recommended level. CONCLUSIONS: diabetic patients that start oral combination therapy with either MF+SU or MF + a PPARg agonist, very frequently have their lipid parameters not at recommended level. A greater focus is required to comprehensively manage their lipid profile, and reduce the cardiovascular risk associated with it.
PDB11 POTENTIAL IMPACT OF LIPID CONTROL AND SUBSEQUENT CARDIOVASCULAR (CV) RISK REDUCTION IN T2DM POPULATION TREATED WITH ORAL COMBINATION THERAPY (OCT) RECAP-DM STUDY
Nocea G 1 , Melero M 2 , Caloto MT 2 ,Yin D 3 1 MSD Spain, Madrid, Spain, 2 Merck, Sharp & Dohme, Madrid, Spain, 3 Merck & Co., Inc, Whitehouse Station, NJ, USA OBJECTIVES: Diabetic patients are at CHD greater risk than the general population. Therefore these patients will benefit from optimal care based on CHD risk evaluation. We assessed the potential impact of risk factors (RF) management on the cardiovascular (CV) risk among T2DM population. METHODS: A retrospective cohort study was conducted in Spain (2006) (2007) . Patients were aged Ն30 years at time of T2DM diagnosis and had added sulphonylurea or PPARg agonist to previous metformin. Patient RFs were assessed for attainment of guideline-defined optimal values. The data for these patients correspond to their last available measurements before add-on therapy. Five-year CV risk was estimated with a A498 Abstracts
